Loading…
Lexeo Therapeutics, Inc. is projected to rise to $5.14 by 2027, a +1% move from its current price of $5.09. LXEO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.88 | $5.09 | $5.31 | 0.00% |
| May 30 | $4.80 | $5.09 | $5.40 | 0.00% |
| May 31 | $4.74 | $5.09 | $5.47 | -0.01% |
| Jun 1 | $4.68 | $5.09 | $5.53 | -0.01% |
| Jun 2 | $4.64 | $5.09 | $5.59 | -0.01% |
| Jun 3 | $4.60 | $5.09 | $5.63 | -0.01% |
| Jun 4 | $4.56 | $5.09 | $5.68 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.56 | $5.09 | $5.68 | -0.01% |
| Week 2 | $4.36 | $5.09 | $5.94 | -0.03% |
| Week 3 | $4.21 | $5.09 | $6.16 | -0.04% |
| Week 4 | $4.08 | $5.09 | $6.34 | -0.06% |
| Week 5 | $3.98 | $5.09 | $6.50 | -0.07% |
| Week 6 | $3.88 | $5.09 | $6.66 | -0.08% |
| Week 7 | $3.80 | $5.09 | $6.80 | -0.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company focused on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 PKP2 gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy ACM and certain forms of dilated cardiomyopathy.
The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer’s disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate.
The company was founded in 2017 and is headquartered in New York, New York.
Lexeo Therapeutics, Inc. trades under the LXEO symbol and sits in the Healthcare sector. Its current price is $5.11 and its market cap is $401.25M, with a public market rank of 3224.
These figures establish its current market position while the company pursues a portfolio of AAVrh10-based gene therapy programs across neurological and cardiac targets. The forecast narrative for the asset shows a path from a 2026 average near its current level toward progressively higher averages in the following years, highlighting long-run upside despite a volatile near term. The annualized forecasts include 2026 average of $5.11 and imply a bullish tilt later in the decade and into the 2030s and beyond, with 2030 average at $6.47 and 2050 average at $17.91.
A major floor 39.8% below — a decisive break under it would weaken the trend.
The nearest floor, 12.0% below — buyers have tended to step in here.
The nearest ceiling, 35.8% above — a clean break opens room to run.
A major ceiling 55.7% above — clearing it would confirm fresh momentum.
Key LXEO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LXEO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.14 | Sell | $5.11 | Sell |
| MA 10 | $5.12 | Sell | $5.20 | Sell |
| MA 20 | $5.49 | Sell | $5.42 | Sell |
| MA 50 | $5.81 | Sell | $5.89 | Sell |
| MA 100 | $6.60 | Sell | $6.40 | Sell |
| MA 200 | $7.16 | Sell | $6.65 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.74 | Neutral |
| Stoch RSI (14) | 57.02 | Neutral |
| CCI (20) | -67.57 | Neutral |
| Williams %R (14) | -62.80 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -12.69 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 37.20 | Neutral |
| TRIX (15) | -0.61 | Sell |
| Awesome (5,34) | -0.69 | Sell |
| Ultimate (7,14,28) | 43.46 | Neutral |
| Momentum (10) | -0.61 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 5.19 | Sell |
| ADX (14) | 16.81 | Neutral |
| ATR (14) | 0.21 | Info |
The 30-day technical picture shows bearish sentiment. The RSI14 is 40, indicating modest downside pressure. The 50-day simple moving average sits at $5.87 and the 200-day simple moving average sits at $7.15.
Support is identified at $4.48 and resistance at $6.91. The 30-day price range spans from $3.82 to $6.84, reflecting a broad trading band and ongoing volatility with an annualized volatility of 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.48 | $5.09 | $6.39 | 0% | Neutral | |
| $3.87 | $5.14 | $7.33 | +1% | Neutral | |
| $3.29 | $4.56 | $6.85 | -10% | Neutral | |
| $3.22 | $4.63 | $7.24 | -9% | Neutral | |
| $4.22 | $6.28 | $10.14 | +23% | Bullish | |
| $4.37 | $6.71 | $11.15 | +32% | Bullish | |
| $4.37 | $6.92 | $11.79 | +36% | Bullish | |
| $4.51 | $7.33 | $12.79 | +44% | Bullish | |
| $4.09 | $6.83 | $12.17 | +34% | Bullish | |
| $3.99 | $6.84 | $12.42 | +34% | Bullish | |
| $5.19 | $10.05 | $19.80 | +97% | Bullish | |
| $7.74 | $17.21 | $38.04 | +238% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.48 | $5.09 | $6.01 | +0.00% |
| June 2026 | $4.36 | $5.18 | $6.34 | +1.69% |
| July 2026 | $4.22 | $5.08 | $6.35 | -1.84% |
| August 2026 | $3.98 | $4.84 | $6.13 | -4.82% |
| September 2026 | $4.00 | $4.90 | $6.30 | +1.41% |
| October 2026 | $4.12 | $5.09 | $6.60 | +3.69% |
| November 2026 | $3.99 | $4.96 | $6.51 | -2.46% |
| December 2026 | $3.86 | $4.83 | $6.39 | -2.60% |
Click any year to see its month-by-month LXEO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Lexeo Therapeutics, Inc.'s 2026 outlook centres on $5.09, within a $4.48 to $6.39 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, LXEO could reach as high as $7.33, with a base case around $5.14 and support toward $3.87 — roughly +1% from $5.09. Price action looks broadly range-bound.
Expect LXEO to range from $3.29 to $6.85 through 2028. The $4.56 average target implies a -10% move from current prices. That is -11% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The LXEO price prediction for 2029 points to an average of $4.63 (low $3.22, high $7.24) — a potential decline of -9% on today's $5.09. Price action looks broadly range-bound.
In 2030, LXEO is projected to trade between $4.22 and $10.14, averaging $6.28 — a potential gain of +23% from today's $5.09. That is up +36% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Lexeo Therapeutics, Inc.'s 2031 outlook centres on $6.71, within a $4.37 to $11.15 range. That is up +7% on the projected 2030 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2032, LXEO could reach as high as $11.79, with a base case around $6.92 and support toward $4.37 — roughly +36% from $5.09. Buyers look set to stay in control over this stretch.
Expect LXEO to range from $4.51 to $12.79 through 2033. The $7.33 average target implies a +44% move from current prices. That is up +6% on the projected 2032 average. Momentum favours further upside here.
The LXEO price prediction for 2034 points to an average of $6.83 (low $4.09, high $12.17) — a potential gain of +34% on today's $5.09. Buyers look set to stay in control over this stretch.
In 2035, LXEO is projected to trade between $3.99 and $12.42, averaging $6.84 — a potential gain of +34% from today's $5.09. That is up 0% on the projected 2034 average. Momentum favours further upside here.
Lexeo Therapeutics, Inc.'s 2040 outlook centres on $10.05, within a $5.19 to $19.80 range. That is up +47% on the projected 2035 average. That marks a +97% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, LXEO could reach as high as $38.04, with a base case around $17.21 and support toward $7.74 — roughly +238% from $5.09. Momentum favours further upside here.
Investing $1,000 in LXEO today (≈ 196.463654 LXEO) could be worth
$3,380.49
+$2,380.49 (+238%) by 2050 · US Dollar
Based on the average projected LXEO price of $17.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LXEOwould be worth at today's price.
$1,000 invested in LXEO on May 27, 2025 (≈ 370.370364 LXEO) would be worth
$1,885.19
+$885.19 (+88.5%) today · 1.89× · US Dollar
Based on a LXEO entry price of $2.7 vs. today's $5.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.12 | $994.14 | -0.6% |
| 1 month ago | $5.63 | $904.89 | -9.5% |
| 3 months ago | $6.9 | $737.68 | -26.2% |
| 6 months ago | $9.86 | $516.23 | -48.4% |
| 1 year ago | $2.7 | $1,885.19 | +88.5% |
| All time (2.6y) ago | $10.05 | $506.47 | -49.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LXEO forecast.
Our base-case forecast reaches $10.00 around 2040.
Implied market cap at $10.00: $785.22M
The multi-year forecast points to a longer horizon bullish drift, led by the 2030, 2040 and 2050 milestones. In 2030 the forecast average is $6.47 with a corresponding ROI figure of 26.5 and a bullish sentiment. The 2040 forecast shows an average of $10.16 with an 98.9 ROI and a bullish stance, while the 2050 forecast envisions an average of $17.91 with a 250.5 ROI and continued bullish momentum.
The yearly path also shows earlier years with neutral sentiment (2026 average $5.11, 2027 $5.16, 2028 $4.51, 2029 $4.66) before the long-run upside arrives. These are estimates, not guarantees, and reflect market-implied expectations subject to significant uncertainty and volatility. The forecast also comes with high volatility as evidenced by the 80% annualized volatility in the near term.
Tap a question to reveal the answer.
2030 Avg $6.47, min $4.26, max $10.63, ROI 26.5, sentiment BULLISH.
2026 Avg $5.11, min $4.48, max $6.47, ROI 0, sentiment NEUTRAL; 2027 Avg $5.16, min $3.85, max $7.46, ROI 1, sentiment NEUTRAL; 2028 Avg $4.51, min $3.21, max $6.87, ROI -11.8, sentiment NEUTRAL; 2029 Avg $4.66, min $3.18, max $7.40, ROI -8.7, sentiment NEUTRAL.
2040 Avg $10.16, min $5.02, max $20.54, ROI 98.9, sentiment BULLISH.
2050 Avg $17.91, min $8.06, max $40.78, ROI 250.5, sentiment BULLISH.
Current price $5.11; Market cap $401.25M; Rank 3224.
Lexeo Therapeutics, Inc. Community Discussion
0Share your Lexeo Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.